From neuroplasticity to behavior:
the therapeutic promise of 2,5-Dimethoxy-4-iodoamphetamine (DOI) as a 5-HT2A agonist

Newsletter # 117



Animal and cellular models


DOI (2,5-Dimethoxy-4-iodoamphetamine) is a synthetic psychedelic and amphetamine analog, lacking the typical stimulant effects of amphetamines. It has potential therapeutic applications in the study of mood disorders and neuropsychiatric conditions due to its action as a potent 5-HT2A receptor agonist, similar to other psychedelics. Thus, it could help elucidate the mechanisms behind serotonin signaling and might contribute to developing treatments for conditions like depression, anxiety, and PTSD.
L-BMAA continues to hold significant interest as understanding its impact on neuronal health and its potential mechanisms of neurotoxicity could provide crucial insights into the common pathophysiology of these diseases.
The Neurofit investigations revealed that:
Neurofit's preclinical data demonstrate that DOI dose-dependently stimulates neurite outgrowth including neurite number, length and branching in rat neuronal cultures, which is believed to be a key mechanism driving behavioral changes. This is further supported by findings that DOI reduces rigid repetitive behaviors in mice, such as marble burying, in a dose-dependent manner—traits often linked to psychiatric disorders. These findings highlight DOI, and 5-HT2A agonists in general, as promising agents for promoting neuroplasticity and addressing repetitive and stereotypic behaviors, key factors in treating various psychiatric conditions.








NEUROFIT offers a range of validated in vitro and in vivo screening tests for psychiatry and neurology.

If you need further information, please do not hesitate to contact us, we will reply within few days. Custom protocol

On a regular basis we distribute newsletters with scientific information on our research services. If you wish to receive these, please :